protect
effect
egg
yolk
colostrum
powder
prepar
hen
cow
vaccin
inactiv
bovin
coronaviru
bcv
antigen
evalu
challeng
model
virul
bcv
strain
twenti
three
calv
bcvfree
herd
randomli
divid
control
sever
treatment
group
calv
oral
challeng
x
tcidso
virul
kakegawa
strain
bcv
h
birth
calv
treatment
group
receiv
either
egg
yolk
powder
cow
colostrum
contain
bcv
specif
antibodi
daili
treatment
antibodi
prepar
start
h
day
postchalleng
control
calv
receiv
antibodi
sever
diarrhea
die
within
day
infect
contrast
calv
fed
milk
contain
egg
yolk
colostrum
neutral
titer
respect
surviv
posit
weight
gain
unlik
treatment
group
result
indic
oral
administ
egg
yolk
colostrum
powder
protect
bcvinduc
diarrhea
neonat
calv
egg
yolk
use
provid
higher
degre
protect
compar
colostrum
powder
titer
basi
treatment
whole
egg
yolk
immun
hen
therefor
provid
efficaci
altern
exist
method
specif
passiv
protect
bcv
elsevi
scienc
bv
bovin
coronaviru
bcv
import
agent
neonat
calf
diarrhea
associ
acut
diarrhea
adult
cattl
refer
winter
dysenteri
viru
known
caus
sever
diseas
higher
mortal
caus
bovin
rotaviru
multipli
small
intestin
larg
intestin
wherea
rotaviru
infect
small
intestin
kapil
et
al
determin
protect
immun
respons
bcv
report
analyz
titer
passiv
activ
antibodi
isotyp
bcv
serum
mucos
surfac
heckert
et
al
b
coronaviru
vaccin
avail
control
bcv
diarrhea
found
efficaci
protect
infect
heckert
et
al
kapil
et
al
case
passiv
immun
report
oral
administr
antibodi
deriv
serum
colostrum
bcv
recent
chicken
egg
yolk
antibodi
use
prophylaxi
treatment
infecti
intestin
diseas
investig
efficaci
chicken
egg
yolk
antibodi
calv
enterotoxigen
escherichia
coli
etec
ikemori
et
al
bovin
rotaviru
object
studi
report
l
evalu
efficaci
chicken
egg
yolk
antibodi
cow
colostrum
antibodi
bcvinduc
diarrhea
calv
bcv
caus
sever
diseas
bovin
rotaviru
compar
therapeut
valu
chicken
egg
yolk
cow
colostrum
antibodi
strain
ncdc
bcv
kindli
provid
dr
murakami
nation
institut
anim
health
tsukuba
japan
strain
origin
isol
mebu
et
al
mebu
et
al
usa
kakegawa
strain
bcv
pathogen
calv
obtain
japanes
associ
veterinari
biolog
virus
certifi
free
adventiti
agent
grown
confluent
human
rectal
tumour
cell
line
eagl
mem
previous
describ
tsunemitsu
et
al
virus
use
challeng
exposur
calv
product
antibodi
chicken
cow
viru
titrat
neutral
test
perform
cell
cultur
grown
microdilut
plate
conduct
method
previous
describ
tsunemitsu
et
al
briefli
titrat
serial
dilut
virus
made
inocul
well
cell
ml
dilut
plate
incub
day
infect
express
median
tissu
cultur
infect
dose
determin
appear
cpe
neutral
test
egg
yolk
colostrum
powder
prepar
suspens
pb
serial
dilut
sampl
mix
volum
viru
suspens
contain
ml
incub
h
two
well
cell
inocul
ml
mixtur
incub
day
neutral
antibodi
titer
express
reciproc
highest
dilut
inhibit
cpe
multipli
antibodi
powder
dilut
factor
two
kind
specif
antibodi
bcv
prepar
egg
yolk
powder
bovin
colostrum
powder
ncdc
antigen
contain
ad
formalin
inactiv
week
antigen
mix
equal
volum
oil
adjuv
mannid
monool
main
biolog
laboratori
main
ml
mixtur
inject
intramuscularli
white
leghorn
hen
six
week
initi
inject
booster
inocul
administ
similar
manner
egg
harvest
week
later
yolk
care
separ
egg
white
appli
spraydri
machin
oper
airinlet
temperatur
dri
egg
powder
store
desicc
room
temperatur
use
cow
use
year
old
histori
diseas
vaccin
bcv
one
ml
formalininactiv
ncdc
vaccin
administ
intramuscularli
two
cow
week
anticip
calv
follow
similar
dose
space
week
apart
earli
colostrum
collect
cow
parturit
appli
spraydri
machin
oper
condit
dri
colostrum
store
desicc
room
temperatur
use
twentythre
colostrumdepriv
newborn
holstein
calv
farm
free
neonat
diarrhea
due
bovin
coronaviru
rotaviru
viral
diarrhea
viru
etec
use
studi
fed
commerci
avail
milk
formula
calv
randomli
distribut
nontreat
control
group
group
egg
powder
treatment
group
group
colostrum
powder
treatment
group
group
h
birth
calv
oral
challengeexpos
virul
kakegawa
strain
fig
l
h
bcv
challeng
treatment
group
given
milk
contain
egg
yolk
colostrum
powder
subsequ
given
time
per
day
day
challeng
exposur
particularli
egg
powder
treatment
group
given
milk
contain
antibodi
titer
g
egg
powder
respect
hand
colostrum
powder
treatment
group
given
milk
contain
antibodi
titer
g
colostrum
powder
respect
control
group
receiv
antibodi
clinic
respons
calf
record
throughout
experi
evalu
term
fecal
consist
score
weight
gain
mortal
fecal
score
done
person
know
treatment
condit
calf
score
done
time
per
day
numer
score
follow
normal
soft
consist
mild
q
diarrhea
sever
wateri
diarrhea
death
cumul
fecal
score
calf
express
total
score
day
examin
fece
infecti
bcv
done
daili
day
cultur
homogen
specimen
cell
day
postchalleng
sampl
middl
part
jejunum
colon
test
infecti
bcv
method
bodi
weight
gain
calv
express
percentag
weight
gain
day
initi
bodi
weight
day
serum
calv
collect
start
end
experi
check
antibcv
antibodi
neutral
test
student
ttest
use
assess
statist
signific
differ
fecal
consist
score
total
posit
day
viru
detect
percentag
bodi
weight
chang
viru
titer
intestin
wherea
fischer
exact
test
use
assess
differ
mortal
treat
control
calv
vitro
neutral
antibodi
titer
egg
yolk
powder
chicken
colostrum
powder
cow
immun
strain
ncdc
almost
homolog
strain
appar
much
differ
magnitud
antibodi
respons
chicken
cow
antibodi
titer
strain
kakegawa
homolog
strain
powder
crossreact
two
strain
neutral
antibodi
test
reveal
close
serolog
relationship
ncdc
kakegawa
strain
titer
use
egg
yolk
colostrum
strain
calv
control
group
group
expos
coronaviru
develop
sever
wateri
diarrhea
includ
mucu
blood
postchalleng
exposur
pe
day
day
die
pe
day
tabl
sever
diarrhea
observ
mean
chang
bodi
weight
time
death
calv
group
treat
antibodi
titer
egg
yolk
antibodi
protect
sever
diarrhea
mortal
three
calv
group
develop
sever
diarrhea
two
calv
die
pe
day
respect
although
calv
group
surviv
infect
cumul
fecal
score
dehydr
result
weight
loss
calv
group
recov
diseas
tabl
diarrhea
temporari
accompani
weight
loss
calv
differ
cumul
fecal
score
weight
gain
group
signific
p
base
isol
coronaviru
fece
intestin
specimen
total
number
day
posit
viru
detect
fece
group
day
shorter
durat
group
differ
signific
titer
coronaviru
intestin
group
low
viru
detect
small
intestin
group
calv
hand
calv
colostrumantibodi
treat
group
develop
sever
wateri
diarrhea
later
die
pe
day
tabl
two
calv
group
also
die
sever
diarrhea
cumul
fecal
score
weight
loss
group
high
control
group
group
calv
recov
diseas
calv
group
develop
wateri
diarrhea
continu
day
cumul
fecal
score
group
high
togeth
low
weight
gain
mean
total
posit
day
viru
detect
fece
among
group
shorter
group
statist
signific
tabl
titer
coronaviru
intestin
group
decreas
increas
colostrum
dose
viru
titer
small
intestin
gener
higher
statist
signific
larg
intestin
group
neutral
antibodi
titer
serum
calv
mean
valu
n
except
group
n
p
bcv
challeng
similar
titer
obtain
day
later
indic
antibodi
administ
egg
yolk
colostrum
enter
system
circul
calv
studi
evalu
efficaci
antibodi
prepar
deriv
egg
yolk
immun
lay
hen
colostrum
immun
cow
experiment
induc
bovin
coronaviru
calf
diarrhea
fill
gap
literatur
concern
passiv
protect
bcv
use
specif
antibodi
data
show
signific
protect
achiev
calv
treat
high
titer
egg
yolk
colostrum
antibodi
challeng
strain
tabl
surviv
coronavirusinduc
mortal
antibodi
titer
use
treatment
calv
egg
yolk
colostrum
powder
respect
particularli
calv
treat
egg
yolk
antibodi
sever
diarrhea
higher
weight
gain
g
egg
yolk
powder
obtain
one
chicken
egg
one
egg
yolk
need
protect
one
calf
diarrhea
cours
treatment
present
data
corrobor
earlier
protect
trial
use
egg
antibodi
specif
etec
etecinfect
calv
ikemori
et
al
minim
antibodi
titer
fatal
diarrhea
found
egg
yolk
colostrum
although
diarrhea
observ
calv
treat
antibodi
powder
cumul
fecal
score
higher
calv
treat
colostrum
treat
egg
yolk
appear
greater
amount
colostrum
powder
egg
yolk
powder
necessari
prevent
diarrhea
viru
titer
intestin
group
calv
high
irrespect
dose
antibodi
given
viru
titer
small
intestin
tend
higher
larg
intestin
group
tabl
specul
continu
viral
prolifer
small
intestin
reason
persist
diarrhea
observ
group
calv
differ
minim
protect
titer
antibodi
powder
egg
yolk
colostrum
may
two
possibl
explan
firstli
avid
antibodi
deriv
colostrum
lower
antibodi
obtain
egg
yolk
ikemori
et
al
compar
colostr
antibodi
bcv
specif
antibodi
egg
yolk
may
react
strongli
stabli
coronaviru
epitop
vivo
neutral
reaction
secondli
less
chicken
antibodi
may
digest
inactiv
gastric
juic
antibodi
escap
digest
stomach
still
function
small
intestin
antibodi
egg
yolk
thought
almost
stabil
slightli
suscept
gastric
juic
mammalian
antibodi
shimizu
et
al
howev
present
data
demonstr
antibodi
egg
yolk
effect
colostr
antibodi
suggest
yolk
compon
egg
yolk
powder
protein
fat
may
protect
immunoglobulin
fraction
digest
enzym
allow
safe
passag
yolk
immunoglobulin
stomach
enough
confer
protect
target
area
small
intestin
calv
hand
colostr
protein
fat
may
suscept
digest
gastric
juic
quantit
less
egg
yolk
conclus
egg
yolk
powder
chicken
immun
bovin
coronaviru
greater
therapeut
potenti
bcvinduc
diarrhea
colostrum
powder
immun
cow
took
four
time
colostr
antibodi
egg
yolk
antibodi
prevent
mortal
calv
oral
egg
yolk
powder
contain
specif
antibodi
may
therefor
provid
altern
approach
passiv
prevent
bcv
infect
field
